

1 Haytham Faraj, Esq. (SBN 291416)
Katherine K. Melik-Stepanyan, Esq. (SBN 315015)
2 Bita R. Tahmasbi, Esq. (SB 354619)
3 **THE LAW OFFICES OF HAYTHAM FARAJ**
8605 Santa Monica Blvd., Suite 44953
4 West Hollywood, California 90069-4109
Telephone: (323) 463-9200
5 Facsimile: (202) 280-1039
Email: service@farajlaw.com
6

7 *Attorneys for Plaintiffs,*
BOBAK SOHRABIAN and MOJGAN HOMAIE
8

9 **SUPERIOR COURT OF THE STATE OF CALIFORNIA**

10 **COUNTY OF ORANGE**

11 BABAK SOHRABIAN and MOJGAN
12 HOMAIE, Individually and as Successors in
Interest to KAMERON SOHRABIAN,
13 deceased;

14 Plaintiffs,

15 vs.

16 BYRAM HEALTHCARE CENTERS, INC., a
Corporation; STERICARE SOLUTIONS, a
17 Corporation; NURSE ASSIST, LLC, a
Limited Liability Company; CITY OF HOPE,
18 a Corporation; NICOLE KARRAS, M.D., an
individual; LISA GUTIERREZ, N.P., an
19 individual; and DOES 1 through 50, inclusive,

20 Defendant(s).
21

30-2024-01438075-CU-PL-CJC

COMPLAINT FOR DAMAGES:

- 1) STRICT PRODUCTS LIABILITY –
MANUFACTURING DEFECT;
- 2) STRICT PRODUCTS LIABILITY –
FAILURE TO WARN;
- 3) NEGLIGENCE;
- 4) NEGLIGENCE – MEDICAL
MALPRACTICE;
- 5) BREACH OF IMPLIED
WARRANTY; AND
- 6) WRONGFUL DEATH

****DEMAND FOR JURY TRIAL****

[DAMAGES EXCEED \$25,000]

Assigned for All Purposes

Judge Andre De La Cruz

24
25 COME NOW, Plaintiffs, BOBAK SOHRABIAN, an individual, and MOJGAN HOMAIE,
26 an individual, for Causes of Action against Defendants, BYRAM HEALTHCARE CENTERS,
27 INC., a Corporation, STERICARE SOLUTIONS, a corporation, NURSE ASSIST LLC, a Limited
28 Liability Company; CITY OF HOPE, a Corporation, NICOLE KARRAS, M.D., an individual,

1 LISA GUTIERREZ, N.P., an individual, and DOES 1 through 50, inclusive, and each of them, as
2 follows:

3 **INTRODUCTION**

4 1. This case arises out of NURSE ASSIST LLC’s (hereinafter “NURSE ASSIST”) recalled 0.9% sodium chloride saline solution (hereinafter “SOLUTION”). NURSE ASSIST
5 manufactured SOLUTION and sold SOLUTION to various brands, including STERICARE
6 SOLUTIONS (hereinafter “STERICARE”). STERICARE distributed its products to various
7 medical supply companies, including BYRAM HEALTHCARE CENTERS, INC. (hereinafter
8 “BYRAM”). NURSE ASSIST’s issued recall resulted from NURSE ASSIST, STERICARE, and
9 BYRAM designing, developing, manufacturing, testing, packaging, promoting, marketing,
10 advertising, distributing, labeling, and selling SOLUTION, a sodium chloride solution that
11 contained a deadly bacterial contamination.
12

13 2. The claims set forth herein arise from Plaintiffs, BOBAK SOHRABIAN and
14 MOJGAN HOMAIE’s (hereinafter, collectively “PLAINTIFFS”) son KAMERON
15 SOHRABIAN’s (hereinafter “DECEDENT”) wrongful death as a result of a bacterial
16 contamination found in a .9% sodium chloride solution.

17 3. For about two years prior to his death, DECEDENT suffered from lymphedema—a
18 condition which caused him to gain wounds and infections around his legs. On or around
19 September of 2023, DECEDENT visited CITY OF HOPE, a hospital, in Duarte, California. Nurse
20 Practitioner LISA GUTIERREZ (hereinafter “LISA GUTIERREZ”) working under NICOLE
21 KARRAS, M.D. (hereinafter “NICOLE KARRAS”) at CITY OF HOPE, prescribed four bottles of
22 0.9% sodium chloride saline solution (bacterial contamination solution hereinafter “SOLUTION”) to
23 DECEDENT to clean his wounds and infections.

24 4. On or around September 29, 2023, BYRAM HEALTHCARE CENTERS, INC.
25 (hereinafter “BYRAM”), a medical supply company, supplied DECEDENT with four bottles of
26 the SOLUTION. NURSE ASSIST, LLC (hereinafter “NURSE ASSIST”) manufactured the
27 SOLUTION. Thereafter, NURSE sold SOLUTION to STERICARE SOLUTIONS (hereinafter
28 “STERICARE”).

1 5. After using one of the four bottles, DECEDENT began suffering from horrible side
2 effects. These side effects included extreme pain, abnormal swelling throughout his entire body, a
3 change in skin color to a purple or blue tint, and pain on his wounds and infections that were not
4 getting better. On or around November 12, 2023, DECEDENT’s pain became intolerable.
5 PLAINTIFFS called 911 and DECEDENT was transported to his local hospital, Hoag Hospital in
6 Newport Beach. After arriving at the hospital, DECEDENT went into septic shock and cardiac
7 arrest. There, DECEDENT passed away. DECEDENT was only twenty-six years old.

8 6. On or around December 7, 2023, a few days shy of one month following
9 DECEDENT’S death, BYRAM sent a recall letter to PLAINTIFFS and DECEDENT. In this letter,
10 BYRAM stated that specific lots of sodium chloride, including the bottles of SOLUTION that they
11 supplied to DECEDENT, were subject to an “Urgent Medical Device Recall.” This recall letter
12 specified that this urgent medical device recall included 0.9% sodium chloride irrigation USP, 250
13 mL bottles, part number 6270, catalog number NA6270. This catalog number included the four
14 SOLUTION bottles that BYRAM supplied PLAINTIFF with just about two months prior.

15 7. PLAINTIFFS later learned that on or around November 6, 2023, about one month
16 prior to BYRAM notifying PLAINTIFFS, NURSE ASSIST and the U.S. Food and Drug
17 Administration (hereinafter “FDA”) issued a voluntary recall on the FDA website. The voluntary
18 recall listed lot numbers that contained the bacterial contamination. To be exact, the recalled
19 product at issue is 0.9% sodium chloride irrigation USP, 250 mL bottle, part number 6270, catalog
20 number NA6270, by the brand name “SteriCare” (hereinafter “SOLUTION”).

21 8. NURSE ASSIST’s company announcement highlighted the population most at risk
22 is immunocompromised patients and “there is a possibility that use of the affected product could
23 potential result in severe or life-threatening adverse events.” The FDA’s announcement stated they
24 are warning consumers, healthcare providers, and healthcare facilities not to use the enlisted
25 recalled products manufactured by NURSE ASSIST, including the SOLUTION supplied to
26 PLAINTIFF. The FDA website explained they were receiving reports of adverse events associated
27 with NURSE ASSIST products, including SOLUTION, because they were nonsterile and
28 contaminated with bacteria. The announcement also stated that this bacterial contamination “could

1 cause serious or life-threatening infections, including bloodstream, urinary tract, open wound/soft
2 tissue, and respiratory infections.” The announcement continued by stating “Patients who are [..]
3 critically ill, have weak immune systems (including newborn infants, pregnant women, and cancer
4 patients) or have chronic diseases are particularly at risk of infection.” Lastly, the FDA’s
5 announcement illustrated that NURSE ASSIST warned healthcare providers, including CITY OF
6 HOPE, NICOLE KARRAS, and LISA GUTIERREZ, on or around the recall date of November 6,
7 2023.

8 9. The SOLUTIONS shipped to DECEDENT posed a lot number that NURSE
9 ASSIST referenced in their recall announcement due to the bacterial contamination. PLAINTIFFS
10 fought for years to ensure DECEDENT recovered and regained his health following his 2016 bone
11 marrow transplant. However, due to this dangerous and defective SOLUTION, PLAINTIFFS lost
12 their only son. PLAINTIFFS understand SOLUTION caused DECEDENT’s death. DECEDENT
13 leaves behind two devastated parents and a sister.

14 **PARTIES**

15 10. At all times relevant and mentioned herein, Plaintiffs BOBAK SOHRABIAN, an
16 individual, and MOJGAN HOMAIE are, and at all times herein mentioned, are residents of the
17 County of Orange, State of California. PLAINTIFFS are the parents of DECEDENT, Kameron
18 Sohrabian.

19 11. Defendant, NURSE ASSIST ACQUISITION COMPANY, LLC is, and at all times
20 mentioned herein, was a limited liability company, with its principal place of business in Haltom
21 City, Texas. Defendant, NURST ASSIST LLC, a Texas Corporation, d/b/a NURSE ASSIST,
22 INC., is the owner and operator of NURSE ASSIST HOLDINGS, LLC (collectively “NURSE
23 ASSIST”), and is, and at all times mentioned herein, was a limited liability company, with its
24 principal place of business located at 4409 Haltom Rd., Haltom City, Texas 76117. Defendant
25 NURSE ASSIST engaged in the business of manufacturing, designing, distributing, selling, and/or
26 licensing into interstate commerce, either directly or indirectly, through third parties or related
27 entities, its product, including SOLUTION. At all relevant times, Defendant BYRAM conducted
28

1 regular or sustained business in California by engaging in substantial commerce and/or business
2 activity in the County of Orange.

3 12. Defendant STERICARE SOLUTIONS is, and at all times mentioned herein was, a
4 privately run organization, organized and existing under the laws of Texas, with its principal place
5 of business in Haltom City, Texas. Defendant STERICARE consists of a team of experts in
6 medical water products. Defendant STERICARE engaged in the business of branding and
7 distributing sterile saline and water solutions, either directly or indirectly through third parties or
8 related entities. Defendant STERICARE conducted regular business in California by selling and
9 distributing its products in California and engaged in substantial commerce and business activity in
10 Orange County.

11 13. Defendant BYRAM HEALTHCARE CENTERS is, and at all times mentioned
12 herein was, a corporation organized and existing under the laws of the State of New Jersey, with its
13 principal place of business in White Plains, New York. Defendant BYRAM is and was engaged in
14 the business of distributing, supplying, selling, marketing, and/or introducing into interstate
15 commerce, either directly or indirectly, products, including the prescription SOLUTION. At all
16 relevant times, Defendant BYRAM conducted regular and sustained business in California by
17 selling and distributing its products in California and engaged in substantial commerce and
18 business activity in Orange County.

19 14. Defendant, CITY OF HOPE is, and at all times mentioned herein was, a registered
20 California Corporation with its principal place of business at 1500 East Duarte Road, Duarte,
21 California 91010. CITY OF HOPE offers various medical services, including wellness and
22 prevention programs, diagnostics, and medical and surgical procedures in Duarte, California.

23 15. Defendant, NICOLE KARRAS M.D., was at all times a licensed Medical Doctor in
24 the State of California. Based on information and belief, NICOLE KARRAS, holds license # A
25 120423 and, at all times relevant and mentioned herein, and currently has full admitting privileges
26 at CITY OF HOPE.

27 16. Defendant, LISA GUTIERREZ, was at all times a licensed Nurse Practitioner in the
28 State of California. Based on information and belief, LISA GUTIERREZ, holds license # A 23361

1 and, at all times relevant and mentioned herein, and currently has full admitting privileges at CITY
2 OF HOPE.

3 17. The true names and capacities of Defendants DOES 1 through 29, inclusive, are
4 unknown to Plaintiffs at this time, who therefore sue said Defendants by such fictitious names.
5 Plaintiffs will amend this Complaint to show the true names and capacities of said Defendants
6 when they have been ascertained.

7 18. The true names and capacities of Defendants DOES 30 through 50, inclusive, are
8 unknown to Plaintiffs at this time, who therefore sue said Defendants by such fictitious names.
9 Plaintiffs will amend this Complaint to show the true names and capacities of said Defendants
10 when they have been ascertained. At all times herein mentioned, DOES 30 to 50, inclusive, and
11 each of them, were, and now are, nurses, physicians surgeons, licensed by the State of California to
12 practice in the State of California or individuals and/or employees at CITY OF HOPE acting as
13 agents, ostensible agents, employees and servants of ST. MARY and some or all of the other
14 within the course and scope of said agency or employment, and exercising prudent, reasonable
15 judgment and care in the selection, employment and control of qualified, trained, experienced
16 nurses, nurse practitioners, nursing personnel, orderlies, assistants, aides and employees under
17 their supervision, control, direction, responsibility and authority while performing services and
18 caring for patients including, but not limited to, DECEDENT.

19 **JURISDICTION & VENUE**

20 19. This Court has jurisdiction over this action pursuant to California Code of Civil
21 Procedure § 410.10. This Court has jurisdiction over the entire action because this is a civil action
22 wherein the matter in controversy, exclusive of interest and costs, exceeds the jurisdictional
23 minimum of the Court. Also, the acts and omissions complained of in this action took place in the
24 City of Irvine in the State of California.

25 20. Venue in this Court is proper because this is a products liability action in which the
26 acts and/or omissions complained took place, in whole or in part, within the venue of this Court,
27 and/or because the Defendants reside, are domiciled, exist, and/or do business within the venue of
28 this Court.

GENERAL ALLEGATIONS

1
2 21. DECEDENT was a 26-year-old male living in Irvine, California with his parents,
3 PLAINTIFFS, and his sister.

4 22. DECEDENT was a cancer survivor. On or around 2016, DECEDENT was
5 diagnosed with lymphoma. He received a bone marrow transplant that same year, at the age of
6 nineteen. Following his bone marrow transplant, DECEDENT went into remission and lived
7 cancer-free.

8 23. PLAINTIFFS continued to care for DECEDENT. PLAINTIFFS consistently took
9 DECEDENT to Doctors appointments, check-up appointments, and follow-up appointments, in an
10 effort to sustain DECEDENT’s health.

11 24. In 2021, DECEDENT developed lymphoedema, a condition where the body tissues
12 swell due to a buildup of lymph fluid. Although Decedent struggled with the side effects of his
13 lymphedema—including swelling, bruising, and wounding in his legs—he managed it with
14 immunosuppressants.

15 25. DECEDENT did not allow this to stop him and was able to live a relatively normal
16 life in the following years. He moved on to obtaining a bachelor’s degree from Chapman
17 University, graduating with honors. DECEDENT was planning on studying for the LSAT, in
18 pursuit of becoming an attorney.

19 26. On or around June of 2023, DECEDENT developed Graft-versus-host
20 disease (hereinafter “GVHD”), a systematic disorder that results from transplanted tissue’s immune
21 cells recognizing the recipient’s body as a foreign body and attacking its cells. DECEDENT was
22 admitted to CITY OF HOPE. During this time, DECEDENT’ lymphedema worsened as he gained
23 greater bruises, wounds, and swelling throughout his legs.

24 27. On or around September of 2023, Defendant, LISA GUTIERREZ, working under
25 NICOLE KARRAS, at CITY OF HOPE prescribed DECEDENT with SOLUTION to cleanse and
26 aid his wounds.

27
28

1 28. SOLUTION is a 0.9% sodium chloride solution. It is supposed to be a sterile saline
2 used to clean open wounds. NURSE ASSIST manufactured SOLUTION and distributed
3 SOLUTION to the brand STERICARE. STERICARE sold SOLUTION under its company name.

4 29. BYRAM is a medical supply company. On or around September 29, 2023,
5 BYRAM supplied DECEDENT with his prescription—four bottles of SOLUTION. BYRAM’s
6 invoice described SOLUTION as, “Catalog# NA6270, Product Description: Sodium Chloride
7 0.9% 250 POUR BOT, Quantity: 4.”

8 30. NURSE ASSIST and STERICARE’S SOLUTION instructed consumers to use
9 SOLUTION for irrigation and flushing of wounds. DECEDENT applied the supposedly sterile
10 saline SOLUTION onto open wounds on his legs, as instructed.

11 31. After using one of the four SOLUTIONs, DECEDENT began suffering from
12 horrible side effects. DECEDENT began forming pain around his wounds. His wounds were not
13 healing, and he felt painful, burning sensations around them. Various wounds gained yellow or
14 scabs, resembling an infection. DECEDENT began forming white discoloration patches around
15 some wounds. Other wounds would not heal, leaving pink and white broken and opened skin
16 around his body.

17 32. DECEDENT also began to swell. DECEDENT did not know why he became so
18 swollen or what was causing this substantially growing swelling. To his knowledge, DECEDENT
19 was using the SOLUTION that LISA GUTIERREZ prescribed properly, according to its
20 instructions. However, DECEDENT’s growing swelling caused the opened skin around his
21 wounds to stretch out, causing him even greater harm and intolerable pain.

22 33. DECEDENT noticed blisters growing on his feet and new wounds around his body.
23 His wounds began forming different forms of discoloration; some showed yellow, white, or green
24 colors, similar to an infection, while others turned into pink and brown colors. DECEDENT’s
25 formed colors of brown or white discoloration around almost all of his wounds.

26 34. DECEDENT’s wounds would not heal, and his legs began bruising, scabbing,
27 changing color. The pain around his wounds became intolerable. PLAINTIFFS found videos on
28 DECEDENT’s phone of him crying alone from his unbearable pain. Photos from his final days

1 depict horribly swollen feet and toes. His feet showed different colors of red, pink, and purple.
2 DECEDENT had tears of skin on his feet, and his legs showed a purple, brown color, with open
3 wounds, scratches, and swelling up to his thighs.

4 35. PLAINTIFFS witnessed their son's demise, pain, and physical reactions.

5 36. On or around November 12, 2023, after about two days of having bilateral lower
6 extremity swelling and pain, DECEDENT was rushed by ambulance to Hoag Hospital in Newport
7 Beach. DECEDENT went into cardiac arrest and, unexpectedly, passed away later that day.

8 37. On or around November 6, 2023, NURSE ASSIST announced a voluntary recall on
9 products that may not be sterile. This recall detailed SOLUTION, a 0.9% sodium chloride solution,
10 and sterile water medical products sold under various brand names, including STERICARE. It
11 instructed users to check their supply of solutions to confirm if they have any of the recalled
12 products and to not use the recalled products.

13 38. Shortly after, the Food and Drug Administration (hereinafter "FDA") also issued a
14 recall, warning "consumers, healthcare providers, and healthcare facilities not to use recalled saline
15 (0.9% sodium chloride) and sterile water medical products manufactured by Nurse Assist, LLC,
16 and sold under various brands." The FDA stated that SOLUTION may not be sterile and
17 potentially contaminated with bacteria. This bacterial contamination could cause serious or life-
18 threatening infections, including bloodstream, urinary tract, open/wound/soft tissue, and
19 respiratory infections.

20 39. The FDA described people with weak immune systems, "including cancer patients"
21 or those who "have chronic diseases" as being "particularly at risk of infection." Nevertheless, any
22 other patient could develop infections after they are exposed to contaminated water-based medical
23 products.

24 40. NURSE ASSIST's recall announcement included SOLUTION, part number 6270,
25 under the brand name STERICARE. This description matched the SOLUTION BYRAM supplied
26 DECEDENT with.

27
28

1 41. Although NURSE ASSIST published its recall on November 6, 2023, neither
2 NURSE ASSIST, STERICARE, nor BYRAM notified, or alerted DECEDENT in a timely
3 manner.

4 42. Although the FDA claims they issued a recall, warning healthcare providers, and
5 healthcare facilities, neither NICOLE KARRAS, LISA GUTIERREZ, nor CITY OF HOPE
6 communicated, alerted, or warned DECEDENT of the recall and life-threatening side effects.

7 43. As a direct and proximate result of using the contaminated saline solution,
8 DECEDENT developed sepsis, which is the cause of DECEDANT’S death on November 12,
9 2023.

10 44. One month later, on or around December 7, 2023, PLAINTIFFs received a letter
11 from BYRAM. BYRAM issued a medical device recall describing saline solution products.
12 BYRAM’s letter specified bottles under lot number 23076070. BYRAM’s medical device recall
13 letter stated, “We received an Urgent Medical Device Recall (see copy attached from one of our
14 suppliers, Nurse Assist, LLC, for specific lots of Sterile 0.9% Normal Saline, USP (100 mL
15 bottles, 250 mL bottles, [...]). This has been an evolving incident with the manufacturer, and
16 Byram has examined its records and determined that you may have received one of these
17 products.”

18 45. The copy attached that BYRAM referenced in their letter included a Field Safety
19 Corrective Action from NURSE ASSIST. NURSE ASSIST’s field safety corrective action
20 attachment was dated November 8, 2023—notably only two days after NURSE ASSIST
21 voluntarily recalled their saline medical products.

22 46. Despite BYRAM’s knowledge of SOLUTION’s dangerous side, BYRAM failed to
23 warn DECEDENT about the recall and dangerous risks associated with SOLUTION’s use.

24 47. BYRAM had knowledge of NURSE ASSIST’s recall and NURSE ASSIST’s Field
25 Safety Corrective Action letter for almost a month until BYRAM sent out a warning letter to
26 DECEDENT. DECEDENT had passed away by the time PLAINTIFFS’s received BYRAM’s
27 recall letter.

28

1 48. As of April 15, 2024, the FDA announced that they have received reports of
2 adverse events associated with the use of NURSE ASSIST products. The FDA claims to be further
3 evaluating this information.

4 49. At all times relevant herein, NURSE ASSIST was engaged in the business of
5 manufacturing, distributing, and selling sterile saline solution products for medical use.

6 50. At all times relevant herein, STERICARE was engaged in the business of
7 manufacturing, distributing, and selling sterile saline solution products for medical use.

8 51. At all times relevant herein, BYRAM was engaged in the business of supplying
9 wound care products, among other items, for medical use.

10 52. At all times relevant herein, CITY OF HOPE, NICOLE KARRAS, and LISA
11 GUTIERREZ were engaged in the business of prescribing and providing medical services to
12 patients.

13 53. At all times relevant herein, LISA GUTIERREZ at CITY OF HOPE prescribed 0.9
14 sodium chloride solution for DECEDENT to begin using.

15 54. At all times relevant herein, NURSE ASSIST manufactured a sterile solution that
16 contained a defect—specifically a bacterial contamination that could result in severe or life-
17 threatening adverse events. NURSE ASSIST distributed SOLUTION to STERICARE.
18 STERICARE sold SOLUTION under their name. Neither NURSE ASSIST nor STERICARE
19 included sufficient warnings of the bacterial contamination on their products. BYRAM supplied
20 DECEDENT with SOLUTION.

21 55. At all times relevant herein, NURSE ASSIST, STERICARE, and BYRAM supplied
22 contaminated products that could foreseeably endanger DECEDENT and users alike.

23 56. At all times relevant herein, NURSE ASSIST, STERICARE, and BYRAM were all
24 integral parts of SOLUTION’s production, marketing, and distribution.

25 57. Following NURSE ASSIST’s recall, NURSE ASSIST warned healthcare providers
26 of SOLUTION’s recall and dangers.

27
28

1 **STRICT PRODUCTS LIABILITY – MANUFACTURING DEFECT**

2 **(Against Defendants NURSE ASSIST, STERICARE, BYRAM, and DOES 1 to 29)**

3 67. PLAINTIFFS hereby re-allege and incorporates by reference each and every
4 allegation contained in the previous paragraphs as though fully set forth herein.

5 68. At all relevant times, defendants designed, developed, tested, manufactured,
6 fabricated, assembled, distributed, bought, sold, inspected, serviced, repaired, maintained,
7 marketed, warranted, supplied, modified, placed, and/or provided SOLUTION, which are
8 defective and unreasonably dangerous to consumers, including DECEDENT, thereby placing
9 SOLUTION products into the stream of commerce. These actions were under the ultimate control
10 and supervision of NURSE ASSIST, STERICARE, BYRAM, and DOES 1 to 29. At all relevant
11 times, defendants designed, researched, developed, manufactured, produced, tested, assembled,
12 labeled, advertised, promoted, marketed, sold, and distributed SOLUTION used by DECEDENT
13 as described herein.

14 69. At relevant times, SOLUTION was manufactured designed, developed,
15 manufactured, and tested by NURSE ASSIST in a defective and unreasonably dangerous
16 condition.

17 70. At relevant times, STERICARE packaged, promoted, marketed, distributed, and
18 labeled SOLUTION in a defective and unreasonably dangerous condition.

19 71. At relevant times, BYRAM distributed or supplied SOLUTION in a defective and
20 unreasonably dangerous condition.

21 72. At all relevant times, NURSE ASSIST, STERICARE, BYRAM, and DOES 1 to 29
22 defectively designed, tested, developed, and manufactured SOLUTION when placed on the
23 market, and was of such a nature that the defects would not be discovered in the normal course of
24 inspection and operation by users thereof. Moreover, SOLUTION failed to provide adequate
25 warnings or instructions concerning the dangerous characteristics of any form of bacterial
26 contamination. In particular, NURSE ASSIST, STERICARE, BYRAM, and DOES 1 to 29,
27 manufactured a dangerous product, SOLUTION, and also failed to provide adequate warnings or
28 instructions concerning SOLUTION’s bacterial contamination.

1 73. NURSE ASSIST, STERICARE, BYRAM, and DOES 1 to 29 researched,
2 developed, designed, tested, manufactured, inspected, labeled, distributed, marketed, promoted,
3 sold, and otherwise released SOLUTION into the stream of commerce, and in the course of same,
4 directly advertised or marketed the products to consumers and end users, including DECEDENT,
5 and therefore had a duty to warn of the risks associated with the use of SOLUTION.

6 74. At all relevant times, NURSE ASSIST, STERICARE, BYRAM, and DOES 1 to 29
7 had a duty to properly test, develop, design, manufacture, inspect, package, label, market, promote,
8 sell, distribute, maintain, supply, provide proper warnings, and take such steps as necessary to
9 ensure SOLUTION did not cause users and consumers to suffer from unreasonable and dangerous
10 risks. NURSE ASSIST, STERICARE, BYRAM, and DOES 1 to 29 had a continuing duty to warn
11 DECEDENT of dangers associated with SOLUTION's use and exposure. NURSE ASSIST,
12 STERICARE, BYRAM, and DOES 1 to 29, as manufacturer, seller, or distributor of medical
13 supplies and saline solutions are held to the knowledge of an expert in the field.

14 75. At all relevant times, NURSE ASSIST, STERICARE, BYRAM, and DOES 1 to 29
15 reached SOLUTION to the intended consumers, handlers, and users in California and throughout
16 the United States, including DECEDENT, without substantial change in the condition, as designed,
17 manufactured, sold, distributed, labeled, and marketed by defendants.

18 76. SOLUTION, as researched, tested, developed, designed, licensed, manufactured,
19 packaged, labeled, distributed, sold, and marketed by NURSE ASSIST, STERICARE, BYRAM,
20 and DOES 1 to 29 was defective in design and formulation in that, when they left the hands of
21 NURSE ASSIST, STERICARE, BYRAM, and DOES 1 to 29 manufacturers and/or suppliers, the
22 foreseeable risks exceeded the alleged benefits associated with their design and formulation.

23 77. Therefore, at all relevant times, SOLUTION, as researched, tested, developed,
24 designed, licensed, manufactured, packaged, labeled, distributed, sold and marketed by NURSE
25 ASSIST, STERICARE, BYRAM, and DOES 1 to 29, was not tested, investigated, or studied in an
26 effective manner and, therefore, was placed into the stream of commerce containing an
27 unreasonably dangerous bacterial contamination.

28

1 78. NURSE ASSIST, STERICARE, BYRAM, and DOES 1 to 29 knew, or should have
2 known that at all times herein mentioned SOLUTION was in a defective condition and was and is
3 inherently dangerous and unsafe.

4 79. DECEDENT used SOLUTION on his open wounds and cuts for a few weeks. After
5 using SOLUTION for some time, DECEDENT began suffering from extreme pain, burning,
6 swelling, and discoloration throughout his body, but predominately on his legs and feet. As such,
7 DECEDENT was exposed to SOLUTION, as described above, without knowledge of
8 SOLUTION’S dangerous characteristics.

9 80. At the time of the DECEDENT’s use of and exposure to SOLUTION, SOLUTION
10 was being used for the purposes and in a manner normally intended.

11 81. NURSE ASSIST, STERICARE, BYRAM, and DOES 1 to 29 had a duty to create
12 and distribute a product that was not unreasonably dangerous for its normal, intended use.

13 82. NURSE ASSIST, STERICARE, BYRAM, and DOES 1 to 29 created and
14 distributed a product that was and is unreasonably dangerous for its normal, intended use.

15 83. NURSE ASSIST, STERICARE, BYRAM, and DOES 1 to 29 designed, researched,
16 manufactured, tested, advertised, promoted, marketed, sold, and distributed SOLUTION with a
17 manufacturing defect, and SOLUTION left the hands of NURSE ASSIST, STERICARE,
18 BYRAM, and DOES 1 to 29 with a manufacturing defect.

19 84. The SOLUTION which NURSE ASSIST, STERICARE, BYRAM, and DOES 1 to
20 29 designed, researched, manufactured, tested, advertised, promoted, marketed, sold, and
21 distributed reached their intended users, including DECEDENT, in a defective and unreasonably
22 dangerous condition due to a bacterial contamination.

23 85. NURSE ASSIST, STERICARE, BYRAM, and DOES 1 to 29 designed, researched,
24 manufactured, tested, advertised, promoted, marketed, sold, and distributed SOLUTION, a
25 defective product, which created an unreasonable risk to the health of consumers and to the
26 DECEDENT in particular. Therefore, NURSE ASSIST, STERICARE, BYRAM, and DOES 1 to
27 29 are therefore strictly liable for the bacterial contamination which cause DECEDENT to
28 unexpectedly pass away.

1 94. Defendants, NURSE ASSIST, STERICARE, and BYRAM, engaged in the
2 manufacturing, selling and distribution of SOLUTION. SOLUTION was defective and
3 unreasonably dangerous when the contaminated lot left the possession of the respective
4 Defendants, NURSE ASSIST, STERICARE, and BYRAM.

5 95. SOLUTION had potential risks associated with its use, including risk of serious or
6 life-threatening infections at the time it was manufactured, sold, and distributed.

7 96. DECEDENT was at CITY OF HOPE for stomach pains and open lesions on his
8 feet. There, LISA GUTIERREZ prescribed DECEDENT SOLUTION to clean his wounds.

9 97. DECEDENT's risk of infections presented a life-threatening danger when he used
10 SOLUTION for its intended purpose and in a foreseeable way on his wounds.

11 98. SOLUTION contained insufficient warnings to alert consumers, including
12 DECEDENT, of the dangerous risks and reactions associated with its use, including but not limited
13 to the propensity to cause a substantial increased risk of serious bodily harm and death.

14 99. DECEDENT nor PLAINTIFFS could not have discovered any defect in
15 SOLUTION through the exercise of reasonable care.

16 100. Defendants', NURSE ASSIST, STERICARE, BYRAM, and DOES 1 to 29, are
17 held to the level of knowledge of an expert in the field. As such, Defendants', NURSE ASSIST,
18 STERICARE, BYRAM, and DOES 1 to 29, knew and know that a contaminated solution cannot
19 be used on open wounds without serious complications.

20 101. The warnings Defendants', NURSE ASSIST, STERICARE, BYRAM, and DOES 1
21 to 29, provided on or with SOLUTION failed to properly warn DECEDENT, and users alike, of
22 the risk of infection.

23 102. Defendants', NURSE ASSIST, STERICARE, BYRAM, and DOES 1 to 29, had a
24 continuing duty to warn the DECEDENT of the dangers associated with SOLUTION.

25 103. Had DECEDENT received adequate warnings regarding the risks of SOLUTION,
26 DECEDENT would not have used it.

27
28

1 104. At all times herein mentioned, SOLUTION was defective, and Defendants',
2 NURSE ASSIST, STERICARE, BYRAM, and DOES 1 to 29, had a duty to warn DECEDENT
3 immediately upon learning of the bacterial contamination.

4 105. As a direct and proximate cause of the defective and inappropriate warnings and the
5 unreasonably dangerous and defective characteristics of SOLUTION, and the Defendants',
6 NURSE ASSIST, STERICARE, BYRAM, and DOES 1 to 29, failure to comply with health and
7 safety standards and requirements, DECEDENT suffered significant injuries. When taken to Hoag
8 Hospital, DECEDENT suffered sepsis due to an infection that resulted in his death.

9 106. As a direct and proximate cause of Defendants' STERICARE, NURSE ASSIST,
10 BYRAM, and DOES 1 to 29, inadequate SOLUTION warning, DECEDENT used SOLUTION on
11 open wounds, causing him to gain a bacterial infection which resulted in his death.

12 107. As a direct and proximate result of Defendants', NURSE ASSIST, STERICARE,
13 BYRAM, and DOES 1 to 29, failing to warn and communicate the recall to DECEDENT,
14 DECEDENT continued to use SOLUTION which caused him to gain a bacterial infection.

15 **THIRD CAUSE OF ACTION**

16 **NEGLIGENCE**

17 **(Against Defendants NURSE ASSIST, STERICARE, BYRAM, and DOES 1 through 29)**

18 108. Plaintiffs hereby incorporate by reference, as if fully set forth herein, each and
19 every allegation set forth in the preceding paragraphs and further alleges as follows:

20 109. Defendants, NURSE ASSIST, STERICARE, BYRAM, and DOES 1 through 29,
21 directly or indirectly, caused SOLUTION to be sold, distributed, packaged, labeled, marketed,
22 promoted, and/or used by DECEDENT.

23 110. At all relevant times, Defendants, NURSE ASSIST, STERICARE, BYRAM, and
24 DOES 1 through 29, had a duty to exercise reasonable care in the design, research, manufacture,
25 marketing, advertisement, supply, promotion, packaging, sale, and distribution of SOLUTION,
26 including the duty to take all reasonable steps necessary to manufacture, promote, and/or sell a
27 product that was not unreasonably dangerous to consumers and users of the product.

1 111. At all relevant times, Defendants, NURSE ASSIST, STERICARE, BYRAM, and
2 DOES 1 through 29, had a duty to exercise reasonable care in the marketing, advertisement, and
3 sale of the SOLUTION products Defendants, NURSE ASSIST, STERICARE, BYRAM, and
4 DOES 1 through 29, had duty of care owed to consumers and the general public included
5 providing accurate, true, and correct information concerning the risks of using SOLUTION and
6 appropriate, complete, and accurate warnings concerning the potential adverse effects of exposure
7 to SOLUTION, and, in particular, the bacterial contamination.

8 112. At all relevant times, Defendants, NURSE ASSIST, STERICARE, BYRAM, and
9 DOES 1 through 29, knew or, in the exercise of reasonable care, should have known of the hazards
10 and dangers of SOLUTION and, specifically, the bacterial contamination.

11 113. Accordingly, at all relevant times, Defendants, NURSE ASSIST, STERICARE,
12 BYRAM, and DOES 1 through 29, knew or, in the exercise of reasonable care, should have known
13 that use of SOLUTION could cause or be associated with DECEDENT's injuries, and thus, create
14 a dangerous and unreasonable risk of injury to the users of these products, including DECEDENT.

15 114. Defendants, NURSE ASSIST, STERICARE, BYRAM, and DOES 1 through 29,
16 also knew or, in the exercise of reasonable care, should have known that users and consumers of
17 SOLUTION were unaware of the risks and the magnitude of the risks associated with use of and/or
18 exposure to SOLUTION.

19 115. As such, Defendants, NURSE ASSIST, STERICARE, BYRAM, and DOES 1
20 through 29, breached their duty of reasonable care and failed to exercise ordinary care in the
21 design, research, development, manufacture, testing, marketing, supply, promotion, advertisement,
22 packaging, sale, and distribution of SOLUTION, in that they manufactured and produced defective
23 herbicides containing a bacterial contamination; knew or had reason to know of the defects
24 inherent in its products; knew or had reason to know that a user's or consumer's exposure to the
25 products created a significant risk of harm and unreasonably dangerous side effects; and failed to
26 prevent or adequately warn of these risks and injuries. Indeed, Defendants, NURSE ASSIST,
27 STERICARE, BYRAM, and DOES 1 through 29, failed to test SOLUTION.

28

1 116. Despite their ability and means to investigate, study, and test the products and to
2 provide adequate warnings, Defendants, NURSE ASSIST, STERICARE, BYRAM, and DOES 1
3 through 29, failed to do so.

4 117. Defendants, NURSE ASSIST, STERICARE, BYRAM, and DOES 1 through 29,
5 negligence included:

6 a. Manufacturing, producing, promoting, formulating, creating, developing,
7 designing, selling, and/or distributing SOLUTION without thorough and adequate pre- and post-
8 market testing;

9 b. Manufacturing, producing, promoting, formulating, creating, developing,
10 designing, selling, and/or distributing SOLUTION while negligently and/or intentionally
11 concealing and failing to disclose the results of trials, tests, and studies of any form of bacterial
12 contamination;

13 c. Failing to provide adequate instructions, guidelines, and safety precautions
14 to those persons Defendants' NURSE ASSIST, STERICARE, BYRAM, and DOES 1 to 29, could
15 reasonably foresee would use and be harmed by SOLUTION;

16 d. Failing to disclose to DECEDENT, users/consumers, and the general public
17 that use of and exposure to SOLUTION presented severe risks of serious or life-threatening
18 infections; and

19 e. Failing to warn DECEDENTS, consumers, and the general public that the
20 SOLUTION's risk of harm was serious or life-threatening.

21 118. Defendants', NURSE ASSIST, STERICARE, BYRAM, and DOES 1 through 29,
22 knew and/or should have known that it was foreseeable consumers such as DECEDENT would
23 suffer injuries as a result of Defendants' failure to exercise ordinary care in the manufacturing,
24 marketing, labeling, distribution, and sale of SOLUTION.

25 119. Defendants' NURSE ASSIST, STERICARE, BYRAM, and DOES 1 through 29,
26 negligence was the proximate cause of decedent's injuries and untimely death, *i.e.*, absent
27 defendants' negligence, DECEDENT would not have developed a bacterial contamination and
28 passed away.

1 20. Defendants', NURSE ASSIST, STERICARE, BYRAM, and DOES 1 through 29,
2 conduct, as described above, was reckless. Defendants, NURSE ASSIST, STERICARE, BYRAM,
3 and DOES 1 through 29, regularly risked the lives of consumers and users of their products,
4 including DECEDENT, with full knowledge of the dangers of their products. Defendants, NURSE
5 ASSIST, STERICARE, BYRAM, and DOES 1 through 29, have made conscious decisions not to
6 redesign, re-label, warn, or inform the unsuspecting public, including DECEDENT.

7 21. As a result of the foregoing acts and omissions, the Decedent suffered from serious
8 and dangerous side effects of a bacterial infection, which resulted in him living his last days in
9 excruciating pain.

10 22. Defendants', NURSE ASSIST, STERICARE, BYRAM, and DOES 1 through 29,
11 conduct was a substantial factor and proximate cause of the serious personal injuries and death of
12 DECEDENT.

13 23. Plaintiffs are informed and believe, and thereon alleges, that at all times herein
14 relevant, that the Defendants', NURSE ASSIST, STERICARE, BYRAM, and DOES 1 through 29,
15 conduct was a substantial factor in causing PLAINTIFFS' damages as alleged herein.

16 24. As a result of the foregoing acts and omissions, Plaintiffs, and each of them, and
17 each of them, have incurred funeral and burial expenses in an amount not yet fully ascertained but
18 according to proof at the time of trial.

19 **FOURTH CAUSE OF ACTION**

20 **NEGLIGENCE – MEDICAL MALPRACTICE**

21 **(Against Defendants CITY OF HOPE, NICOLE KARASS, and LINDA GUTIERREZ, and**
22 **DOES 30 to 50)**

23 25. Plaintiffs hereby incorporate by reference, as if fully set forth herein, each and
24 every allegation set forth in the preceding paragraphs and further alleges as follows:

25 26. DECEDENT was at CITY OF HOPE for stomach pains and open lesions on his
26 feet. There, LISA GUTIERREZ prescribed DECEDENT SOLUTION to clean his wounds.

27 27. DECEDENT's risk of infections presented a life-threatening danger when he used
28 SOLUTION for its intended purpose and in a foreseeable way on his wounds.

1 128. SOLUTION contained insufficient warnings to alert consumers, including
2 DECEDENT, of the dangerous risks and reactions associated with its use, including but not limited
3 to the propensity to cause a substantial increased risk of serious bodily harm and death.

4 129. On or around November 6, 2023, NURSE ASSIST issued a recall. In their recall
5 statement, NURE ASSIST stated that they notified healthcare providers and healthcare facilities,
6 including Defendants', CITY OF HOPE, NICOLE KARRAS LISA GUTIERREZ, and DOES 30
7 to 50, communicating SOLUTION's recall, due to a life-threatening bacterial contamination.

8 130. Defendants', CITY OF HOPE, NICOLE KARRAS LISA GUTIERREZ, and DOES
9 30 to 50, were made aware of the recall. Defendants', CITY OF HOPE, NICOLE KARRAS LISA
10 GUTIERREZ, and DOES 30 to 50, learned SOLUTION was contaminated and the foreseeable
11 risks associated with SOLUTION while DECEDENT continued using SOLUTION.

12 131. Defendants', CITY OF HOPE, NICOLE KARRAS LISA GUTIERREZ, and DOES
13 30 to 50, failed to communicate and warn DECEDENT that NURSE ASSIST recalled
14 SOLUTION, and the risks and side effects, upon learning this information.

15 132. DECEDENT, individually and through DECEDENT's prescribing/treating
16 physicians, reasonably relied on the skill, superior knowledge, and judgment of DEFENDANTS.

17 133. Defendants', Defendants', CITY OF HOPE, NICOLE KARRAS LISA
18 GUTIERREZ, and DOES 30 to 50, had a continuing duty to warn the DECEDENT of the dangers
19 associated with SOLUTION.

20 134. Defendants', CITY OF HOPE, NICOLE KARRAS LISA GUTIERREZ, and DOES
21 30 to 50, had a duty to keep DECEDENT informed of any risks related to his care. Yet,
22 Defendants', CITY OF HOPE, NICOLE KARRAS LISA GUTIERREZ, and DOES 30 to 50,
23 failed to notify DECEDENT of their prescribed product—SOLUTION—deadly propensity.

24 135. Although NURSE ASSIST notified health care facilities and providers,
25 Defendants', CITY OF HOPE, NICOLE KARRAS LISA GUTIERREZ, and DOES 30 to 50,
26 failed to notify DECEDENT of the bacterial contamination. DECEDENT was treated at CITY OF
27 HOPE when battling cancer. Being that DECEDENT is a cancer survivor, and CITY OF HOPE,
28 NICOLE KARRAS, LISA GUTIERREZ, and DOES 30 to 50, knew of DECEDENT'S health

1 conditions, it was imperative for CITY OF HOPE, NICOLE KARRAS, LISA GUTIERREZ, and
2 DOES 30 to 50, to communicate this information to DECEDENT, upon gaining notice.

3 136. Defendants', CITY OF HOPE, NICOLE KARRAS LISA GUTIERREZ, and DOES
4 30 to 50, failure to notify DECEDENT resulted in DECEDENT further using SOLUTION on
5 susceptible and open cuts, wounds, and lesions.

6 137. DECEDENT's lesions, open cuts, and wounds only worsened when he further used
7 SOLUTION. DECEDENT gained significant discoloration throughout his legs and feet, bodily
8 swelling, worsening wounds, burning sensations, and continued pain because he continued to use
9 SOLUTION.

10 138. NURSE ASSIST's recall was significant in that it was due to a severe or life-
11 threatening risk. Moreover, DECEDENT's condition, as a cancer survivor and
12 immunocompromised patient, increased his risk of harm if continuing to use SOLUTION.
13 Defendants', CITY OF HOPE, NICOLE KARRAS LISA GUTIERREZ, and DOES 30 to 50,
14 failure to warn DECEDENT of this deadly side-effect.

15 139. Had DECEDENT received adequate warnings regarding the risks of SOLUTION,
16 DECEDENT would not have used it.

17 140. As a direct and proximate cause of the defective and inappropriate warnings and the
18 unreasonably dangerous and defective characteristics of SOLUTION, and the Defendants', CITY
19 OF HOPE, NICOLE KARRAS, LISA GUTIERREZ, and DOES 30 to 50, failure to comply with
20 health and safety standards and requirements, DECEDENT suffered significant injuries. When
21 taken to Hoag Hospital, DECEDENT suffered sepsis due to an infection that resulted in his death.

22 141. As a direct and proximate cause of Defendants' CITY OF HOPE, NICOLE
23 KARRAS, LISA GUTIERREZ, and DOES 30 to 50, failure to warn DECEDENT of
24 SOLUTION's bacterial contamination, DECEDENT used SOLUTION on open wounds, causing
25 him to gain a bacterial infection which resulted in his death.

26 **FIFTH CAUSE OF ACTION**

27 **BREACH OF IMPLIED WARRANTY**

28 **(Against Defendants NURSE ASSIST, STERICARE, BYRAM, and DOES 1 through 29)**

1 142. Plaintiffs hereby incorporate by reference, as if fully set forth herein, each and
2 every allegation set forth in the preceding paragraphs and further alleges as follows:

3 143. At all relevant times, Defendants', NURSE ASSIST, STERICARE, BYRAM, and
4 DOES 1 through 29, engaged in the business of testing, developing, designing, manufacturing,
5 selling, distributing, and promoting SOLUTION, which was and are defective and unreasonably
6 dangerous to consumers, including decedent, thereby placing SOLUTION into the stream of
7 commerce.

8 144. Before the time DECEDENT was exposed to the aforementioned SOLUTION,
9 Defendants', NURSE ASSIST, STERICARE, BYRAM, and DOES 1 through 29, impliedly
10 warranted to its consumers, including decedent, that SOLUTION was of merchantable quality and
11 safe and fit for the use for which they were intended.

12 145. Defendants', NURSE ASSIST, STERICARE, BYRAM, and DOES 1 through 29,
13 failed to disclose that SOLUTION has dangerous propensities when used as intended and that use
14 of and/or exposure to SOLUTION carries an increased risk of developing severe injuries,
15 including DECEDENT's injuries and death.

16 146. SOLUTION was expected to reach and did in fact reach consumers and users,
17 including decedent, without substantial change in the condition in which they were manufactured
18 and sold by Defendants' NURSE ASSIST and STERICARE.

19 147. Defendants', NURSE ASSIST, STERICARE, BYRAM, and DOES 1 through 29,
20 intended that SOLUTION be used in the manner in which DECEDENT, in fact, used them and
21 which Defendants', NURSE ASSIST, STERICARE, BYRAM, and DOES 1 through 29,
22 impliedly warranted to be of merchantable quality, safe, and fit for this use, despite the fact that
23 SOLUTION was not adequately tested or researched.

24 148. In reliance upon Defendants', NURSE ASSIST, STERICARE, BYRAM, and
25 DOES 1 through 29, implied warranty, DECEDENT used SOLUTION as instructed and labeled
26 and in the foreseeable manner intended.

27 149. DECEDENT could not have reasonably discovered or known of the risks of serious
28 injury associated with SOLUTION.

1 150. Defendants', NURSE ASSIST, STERICARE, BYRAM, and DOES 1 through 29,
2 breached its implied warranty to DECEDENT in that SOLUTION were not of merchantable
3 quality, safe, or fit for their intended use, or adequately tested. SOLUTION has dangerous
4 propensities when used as intended and can cause serious injuries, including those injuries
5 complained of herein.

6 151. Defendants, NURSE ASSIST, STERICARE, BYRAM, and DOES 1 through 29,
7 actions, manufacturing, labeling, selling, and distributing SOLUTION posed harm which far
8 outweighed its benefit, rendering SOLUTION more dangerous than an ordinary consumer or user
9 would expect and more dangerous than alternative products.

10 152. As a direct and proximate result of Defendants', NURSE ASSIST, STERICARE,
11 BYRAM, and DOES 1 through 29, breach of implied warranty, the DECEDENT suffered from
12 serious and dangerous side effects including a bacterial infection. Further, DECEDENT suffered
13 life-threatening bacterial contamination and severe personal injuries and what eventually led to his
14 death.

15 153. As a direct and proximate result of Defendants', NURSE ASSIST, STERICARE,
16 BYRAM, and DOES 1 through 29, breach of implied warranty, DECEDENT used SOLUTION on
17 his open wounds and cuts, causing him to gain a bacterial infection that resulted in him losing his
18 life.

19 154. Defendants', NURSE ASSIST, STERICARE, BYRAM, and DOES 1 through 29,
20 manufactured, packaged, distributed, and labeled SOLUTION was a substantial factor and
21 proximate cause of DECEDENT's death sustained.

22 155. PLAINTIFFS are informed and believe, and thereon alleges, that at all times herein
23 relevant, that the Defendants', NURSE ASSIST, STERICARE, BYRAM, and DOES 1 through 29,
24 conduct was a substantial factor in causing PLAINTIFFS damages as alleged herein.

25 156. As a further result of the negligence of said Defendants, and each of them,
26 PLAINTIFFS, and each of them, have incurred funeral and burial expenses in an amount not yet
27 fully ascertained but according to proof at the time of trial.

28 **SIXTH CAUSE OF ACTION**

1 **WRONGFUL DEATH**

2 **(Against all Defendants, and DOES 1 to 50, Inclusive)**

3 157. A Plaintiffs hereby incorporate by reference, as if fully set forth herein, each and
4 every allegation set forth in the preceding paragraphs and further alleges as follows:

5 158. During all periods of time hereinbelow mentioned, NURSE ASSIST manufactured
6 and sold a saline solution that contained a bacterial contamination. NURSE ASSIST sold
7 SOLUTION to different companies, including STERICARE.

8 159. BYRAM engaged in supplying and distributing various medical prescriptions,
9 including SOLUTION, to DECEDENT.

10 160. NURSE ASSIST and STERICARE sold and marketed SOLUTION, and BYRAM
11 distributed solution, without warning DECEDENT and consumers alike of the associated dangers
12 and risks.

13 161. SOLUTION was one of the products recalled on November 6, 2023. SOLUTION
14 had a bacterial contamination and, thus, was not sterile.

15 162. DEFENDANTS, each and every one of them, learned of the bacterial
16 contamination. NURSE ASSIST announced a recall on November 6, 2023, stating that they have
17 warned medical providers and health care facilities of the life-threatening contamination associated
18 with SOLUTION. NURSE ASSIST forwarded, communicated, and/or provided BYRAM within a
19 Field Safety Corrective Action letter on November 8, 2023.

20 163. During said periods of time, DECEDENT used SOLUTION in a reasonable manner
21 on his open skin wounds.

22 164. Defendants' NURSE ASSIST, STERICARE, BYRAM, and DOES 1 to 29,
23 breached their duty when they negligently and carelessly failed to warn, contact, inform, instruct,
24 and communicate DECEDENT of the recall in a timely manner, on or around the time the recall
25 was announced.

26 165. At all relevant times, DECEDENT was a cancer survivor and
27 immunocompromised.

28

1 166. As a direct and proximate cause of NURSE ASSIST's manufacturing,
2 STERICARE's selling, and BYRAM's distributing SOLUTION, DECEDENT suffered bodily
3 injury, resulting in pain and suffering, mental anguish, loss of capacity of the enjoyment of live,
4 shortened life expectancy, expenses of hospitalization, loss of earnings, loss of ability to earn
5 money, and death.

6 167. As a direct and proximate cause of DEFENDANTS and DOES 1 to 50, inclusive,
7 failing to warn DECEDENT that SOLUTION contained a life-threatening bacterial contamination,
8 DECEDENT used SOLUTION on his open wounds

9 168. DECEDENT died as a direct and proximate cause of Defendants' NURSE ASSIST,
10 STERICARE, BYRAM, and DOES 1 to 50, negligent and wrongful conduct in connection with
11 the design, development, manufacture, testing, packaging, promoting, marketing, advertising, and
12 distribution of SOLUTION.

13 169. Defendants' NURSE ASSIST, STERICARE, BYRAM, and DOES 1 to 29, conduct
14 in design, development, manufacture, testing, packaging, promoting, marketing, advertising, and
15 distribution was a substantial and proximate cause of DECEDENT's sustained personal injuries
16 and death.

17 170. DEFENDANTS and DOES 1 to 50, INCLUSIVE, conduct in failing to warn
18 DECEDENT, immediately, as they learned of the bacterial contamination was a substantial and
19 proximate cause in DECEDENT's further use of SOLUTION. As DECEDENT continued to use
20 SOLUTION, lesions, wounds, and cuts only became further inflamed, infected, and discolored,
21 causing him extreme pain.

22 171. DEFENDANTS and DOES 1 to 50, INCLUSIVE, failure to timely and effectively
23 notify DECEDENT, resulted in DECEDENT to gain a bacterial infection which led to
24 DECEDENT's November 12, 2023, hospitalization. DECEDENT was unaware as to any infection
25 and had no knowledge as to what was contributing to his extreme pain. At the hospital,
26 DECEDENT unexpectedly went into septic shock. DEFENDANTS' and DOES 1 to 50, inclusive,
27 failure to warn DECEDENT was a substantial and proximate cause in his death.

28

1 172. As a further direct and legal result of the aforesaid negligence, carelessness, and
2 unskillfulness of DEFENDANTS and DOES 1 to 50, inclusive, PLAINTIFFS incurred expenses
3 for funeral, burial and other related costs, in an amount according to proof.

4 **PRAYER FOR RELIEF**

5 **(ON THE FIRST THROUGH THIRD CAUSES OF ACTION)**

6 WHEREFORE, Plaintiffs, BOBAK SOHRABIAN and MOJGAN HOMAIE, hereby pray for
7 judgment against Defendants, and each of them, jointly and severally as follows:

- 8 1. Awarding compensatory damages in excess of the jurisdictional amount, including, but not
9 limited to pain, suffering, emotional distress, loss of enjoyment of life, and other non-
10 economic damages in an amount to be determined at trial of this action;
- 11 2. Awarding economic damages in the form of medical expenses, out of pocket expenses and
12 other economic damages in an amount to be determine at trial of this action;
- 13 3. Punitive and/or exemplary damages for the wanton, willful, fraudulent, and reckless acts of
14 the Defendants who demonstrated a complete disregard and reckless indifference for the
15 safety and welfare of the general public and to the Plaintiffs in an amount sufficient to
16 punish Defendants and deter future similar conduct, to the extent allowed by applicable
17 law;
- 18 4. For costs of funeral and burial expenses for Decedent;
- 19 5. For other further general and special damages in a sum according to proof at trial;
- 20 6. Pre-judgment interest;
- 21 7. Post-judgment interest;
- 22 8. Awarding Plaintiffs reasonable attorneys' fees;
- 23 9. Awarding Plaintiffs the costs of these proceedings; and
- 24 10. Such other and further relief as this Court deems just and proper.

25 ///

26 ///

27 ///

28 ///

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

DATED: November 5, 2024

THE LAW OFFICES OF HAYTHAM FARAJ



By:

HAYTHAM FARAJ, ESQ.
KATHERINE MELIK-STEPANYAN, ESQ.
BITA R. TAHMASBI, ESQ.
Attorneys for Plaintiffs, BOBAK
SOHRABIAN and MOJGAN HOMAIE

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

DEMAND FOR JURY TRIAL

Plaintiffs, BOBAK SOHRABIAN AND MOJGAN HOMAIE, hereby formally demand a trial by jury on all issues so triable, as allowed by California law.

DATED: November 5, 2024

THE LAW OFFICES OF HAYTHAM FARAJ



By:

HAYTHAM FARAJ, ESQ.
KATHERINE MELIK-STEPANYAN, ESQ.
BITA R. TAHMASBI, ESQ.
Attorneys for Plaintiffs, BOBAK
SOHRABIAN and MOJGAN HOMAIE